{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:23:35Z","timestamp":1760909015964},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T00:00:00Z","timestamp":1481328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00280-016-3215-3","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T13:18:02Z","timestamp":1481375882000},"page":"139-146","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor"],"prefix":"10.1007","volume":"79","author":[{"given":"Changhoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jeong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Mo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heung-Moon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"key":"3215_CR1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063\u20133072","journal-title":"J Clin Oncol"},{"key":"3215_CR2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224\u2013233","journal-title":"N Engl J Med"},{"key":"3215_CR3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Simron S, Buzzoni R et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968\u2013977","journal-title":"Lancet"},{"key":"3215_CR4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501\u2013513","journal-title":"N Engl J Med"},{"key":"3215_CR5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E, Peeters M et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005\u20132012","journal-title":"Lancet"},{"key":"3215_CR6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","volume":"117","author":"JR Strosberg","year":"2010","unstructured":"Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT et al (2010) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268\u2013275","journal-title":"Cancer"},{"key":"3215_CR7","first-page":"194","volume":"34","author":"JR Strosberg","year":"2016","unstructured":"Strosberg JR, Wolin EM, Chasen B, Kulke MH, Bushnell DL, Caplin ME et al (2016) NETTER-1 phase III: progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate. ASCO Meet Abstr 34:194","journal-title":"ASCO Meet Abstr"},{"key":"3215_CR8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"Kulke MH, Anthony LB, Bushnell DL, de Herder WW (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39:735\u2013752","journal-title":"Pancreas"},{"key":"3215_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185","journal-title":"Neuroendocrinology"},{"key":"3215_CR10","volume-title":"WHO classification of tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. World Health Organization, Geneva"},{"key":"3215_CR11","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","volume":"118","author":"DY Oh","year":"2012","unstructured":"Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK et al (2012) Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer 118:6162\u20136170","journal-title":"Cancer"},{"key":"3215_CR12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","volume":"19","author":"F Panzuto","year":"2014","unstructured":"Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC et al (2014) Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19:966\u2013974","journal-title":"Oncologist"},{"key":"3215_CR13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"},{"key":"3215_CR14","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","volume":"26","author":"MH Kulke","year":"2008","unstructured":"Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403\u20133410","journal-title":"J Clin Oncol"},{"key":"3215_CR15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","volume":"26","author":"E Grande","year":"2015","unstructured":"Grande E, Capdevila J, Castellano D, Teul\u00e9 A, Dur\u00e1n I, Fuster J et al (2015) Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol 26:1987\u20131993","journal-title":"Ann Oncol"},{"key":"3215_CR16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","volume":"109","author":"HK Ahn","year":"2013","unstructured":"Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH et al (2013) Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer 109:1414\u20131419","journal-title":"Br J Cancer"},{"key":"3215_CR17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","volume":"16","author":"AT Phan","year":"2015","unstructured":"Phan AT, Halperin DM, Chan JA, Fogelman DR et al (2015) Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 16:695\u2013703","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3215-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:40:35Z","timestamp":1498369235000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3215-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3215-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,10]]}}}